Intensity modulated radiotherapy with IGRT for Post cricoid and upper esophageal cancer: Prospective observational study

Varian Medical Systems Inc0 sites0 target enrollmentStarted: TBDLast updated: November 24, 2021

Trial Snapshot

No summary available.

•1.Biopsy-proven squamous cell carcinoma of the post cricoid and upper esophagus, with AJCC 7th edition stage T1-3N0-1,2M0
•2.Lesions of the cervical and upper thoracic esophagus but not involving the mid and lower third of thoracic esophagus
•3.Suitable for radical treatment with RT alone or Concurrent Chemo-radiotherapy
•4.No significant co-morbidities that would interfere with treatment
•5.Reliable for follow-up and signed informed consent.
•6.Karnofsky performance status (KPS) between 70 and 100

•1.Age less than 18;
•2.Previous treatment (e.g. chemotherapy, radiation therapy, laser therapy or surgery) for esophageal or head and neck cancer (gastrostomy or PEG does not constitute exclusion criteria);
•3.Previous thoracic radiation therapy for any cause;
•4.Evidence of other uncontrolled malignancies;
•5.Severe compromised pulmonary function due to pulmonary disease eg. COPD
•6.Scoliosis/kyphosis;
•7.Failure to complete all baseline assessments required for the study.
•8.Dysfunctional larynx (gross exolaryngeal extension, need for tracheostomy)

Sponsor

Varian Medical Systems Inc